|
|
125 Shoreway Road, Ste B
San Carlos, CA 94070 USA
phone:(650) 226-0120
fax:(650) 631-3731
|
|
| Symbol |
Private |
| Founded |
1999 |
| Employees |
29 |
|
|
| www.biocardia.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Cardiovascular Regereation and Drug Delivery |
|
| Management |
| Peter Altman, PhD, President & CEO, Director; Andrew Mackenzie, Vice President of Operations; Gulshan Shaver, Vice President of Intellectual Property and Licensing; Didier Rouy, MD PhD, Senior Director of Research & Clinical Development; Ron Koronkowski, Senior Director, Quality Assurance |
| |
|
|
| |
|
| Keywords |
| transendocardial, intramyocardial, delivery catheter, fixation, hollow helical needle |
|
|
|
| Description |
|
BioCardia specializes in cardiac regenerative medicine. The company currently partners for development of combination products related to cell and gene based cardiac repair. Four programs are under approved INDs for clinical investigation at this time. |
|
| Products / Services |
BioCardia's Helical Infusion Catheter is under investigational use in the United States and CE Mark is anticipated in early 2010. The company's Morph Universal Deflectable Guide Catheters and Morph AccessPro Steerable Introducers are FDA cleared and sold directly in the United States. CE Mark for this product line is also expected in 2010.
|
|
| Technology / Differentiation |
| BioCardia's catheter platform enables safe and efficient delivery of biologics to the heart in a routine clinical setting. The company's catheters attach to the heart wall with a corkscrew helical needle, enabling optimal navigation when used in conjunction with the companies FDA cleared Morph Universal Deflectable Guide Catheters. |
|
| Market / Customers |
BioCardia's primary customer is the interventional cardiologist, though its other customers include large health care product firms and small cap privately held firms. The market for cardiac regeneration is estimated to be in excess of $10B and includes all of the large cardiovascular indications of heart failure, chronic myocardial ischemia, cardiac conduction disorders, and acute myocardial infarction.
|
|
| Competitors / Substitutes / Alternatives |
Johnson and Johnson Biological Delivery System is the only active competitor. Many competitors are waiting in the wings to attempt to follow our efforts.
|
|
| Strategy |
Sell catheters that are valued by the customer at a fair price. Partner under reasonable terms agnostically for development of combination products to treat cardiovascular disease. Be the worlds leader for local biotherapeutic therapy in cardiology. Be first to market. Be respected by our customers for our integrity, intelligence, and hard work.
|
|
| Funding |
| The company last raised a series D in 2009 of $11M with new and existing investors. A total of $17M has been raised to date from corporate and individual investors. |
|
| Status |
| The company's products have been used in thousands of interventions worldwide and generate revenues > $1M. The company aims for profitability for all product lines, even in advance of stem cell based therapies being commercially available in the United States.
BioCardia is a sponsor of two autologous stem cell programs in active Phase IIA clinical trials in the United States. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members